# Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

> **NCT02262455** · PHASE1 · COMPLETED · sponsor: **Santa Maria Biotherapeutics** · enrollment: 32 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Endometrial Cancer
- Solid Tumors

## Interventions

- **DRUG:** STM 434
- **DRUG:** Liposomal doxorubicin

## Key facts

- **NCT ID:** NCT02262455
- **Lead sponsor:** Santa Maria Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2017-01-13
- **Final completion:** 2017-01-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262455, "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02262455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*